EP0918539B1 - Impfstoff gegen tumore der b-lymphozyten - Google Patents

Impfstoff gegen tumore der b-lymphozyten Download PDF

Info

Publication number
EP0918539B1
EP0918539B1 EP97905966A EP97905966A EP0918539B1 EP 0918539 B1 EP0918539 B1 EP 0918539B1 EP 97905966 A EP97905966 A EP 97905966A EP 97905966 A EP97905966 A EP 97905966A EP 0918539 B1 EP0918539 B1 EP 0918539B1
Authority
EP
European Patent Office
Prior art keywords
antigen
antibody
cell
malignant
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP97905966A
Other languages
English (en)
French (fr)
Other versions
EP0918539A4 (de
EP0918539A1 (de
Inventor
Mircea C. Popescu
Larry Kwak
Augusto C. Ochoa
Larry Boni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomira USA Inc
Original Assignee
Biomira USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomira USA Inc filed Critical Biomira USA Inc
Publication of EP0918539A1 publication Critical patent/EP0918539A1/de
Publication of EP0918539A4 publication Critical patent/EP0918539A4/de
Application granted granted Critical
Publication of EP0918539B1 publication Critical patent/EP0918539B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Definitions

  • the present invention relates to methods for inducing humoral and cellular immune responses against malignant B cells.
  • this invention is directed to methods for producing an integrated immunologic response against tumor cells using antigens that are associated with a B-cell malignancy.
  • TAAs tumor associated antigens
  • CEA carcinoembryonic antigen
  • Ab2s anti-idiotype antibodies
  • TAAs tumor necrosis factor-associated antigen
  • Ab2 ⁇ antibodies directed against the variable regions of conventional antibodies
  • Certain Ab2s can mimic the three- dimensional structure of the nominal antigen, and thus Ab2 and antigen can bind with the same regions of the Ab1-combining site. Jerne et al., EMBO J. 1 : 243 (1982); Losman et al., Int. J. Cancer 46 : 310 (1990); Losman et al., Proc. Nat'l Acad. Sci.
  • antigen mimicry properties of anti-idiotype antibodies have led to the use of Ab2 ⁇ as surrogate antigens (or idiotype vaccines), when the nominal antigen is not readily available or when the host is tolerant to the nominal antigen.
  • immunization with Ab2 ⁇ mimicking certain TAA creates specific immunity to the TAA and protect against subsequent tumor growth. See, for example, Nepom et al., Proc. Nat'l Acad. Sci. USA 81: 2864 (1984); Raychaudhuri et al., J. Immunol. 139: 271 (1987).
  • anti-idiotype vaccines have been developed against infectious organisms, such as Streptococcus pneumoniae [McNamara et al., Science 226: 1325 (1984)], hepatitus B virus [Kennedy et al., Science 22.3 : 930 (1984)], Escherichia coli K13 [Stein et al., J. Exp. Med. 160: 1001 (1984)], Schistosomiasis mansoni [Kresina et al., J. Clin. Invest. 83 : 912 (1989)], and Moloney murine sarcoma virus [Powell et al., J. Immunol. 142: 1318 (1989)].
  • Cancer patients receiving an anti-TAA of animal origin will usually produce antibodies to the Ab1 and these anti-immunoglobulin antibodies include Ab2.
  • the anti-idiotype response also may include the generation of T cells (T2). Fagerberg et al ., Cancer Immunol. Immunother. 37: 264 (1993).
  • Ab2 may subsequently induce a humoral and cellular anti-anti-idiotypic response, Ab3 and T3, respectively, which may recognize the same epitope as Ab1. Id. This is a problem because it can reduce the effectiveness of the immune response.
  • a therapeutic liposomal composition comprising:
  • Such malignant B-cells include those associated with lymphoma, chronic lymphocytic leukemia and multiple myeloma.
  • the composition of the invention additionally comprises a tumor-associated antigen that is not an antibody or antibody fragment.
  • additional TAAs include, e.g., MUC-1, Epstein Barr Virus (EBV) antigen or an antigen associated with Burkitt's lymphoma.
  • EBV Epstein Barr Virus
  • compositions of the invention additionally comprise normal B-cell antigens such as HLA antigens.
  • Examples of said at least one other cytokine include M-CSF, GM-CSF and IFN-gamma.
  • the lipid molecule may be selected from the group consisting of phospholipid, cholesterol, and glycolipid and derivatives of these lipids.
  • the compositions of the invention also comprise a carrier protein, e.g., albumin.
  • composition in another embodiment, is used in the manufacture of a medicament for inducing humoral and cellular immune responses against malignant B-cells in a mammal, or for treating a B-cell malignancy.
  • Methals of preparing compositions of the invention are also provided.
  • composition is composed of three categories of molecules:
  • composition structure comprises a microscopic vesicle composed of lipid(s), cytokine(s) and at least one B-cell malignancy-associated antigen.
  • composition of the invention may also include an adjuvant or carrier protein, such as albumin.
  • An antigen is a substance that, upon introduction into a vertebrate animal, stimulates the production of antibodies.
  • An idiotype is an antigenic determinant of the variable region of an antibody.
  • a B-cell malignancy associated antigen is a molecule produced by or associated with malignant B cells, but which is not normally expressed, or is expressed at very low levels, by a non-malignant B-cell.
  • B-cell malignancy associated antigens include antibodies. antibody fragments produced by malignant B-cells, and other non-antibody antigens produced by or associated with malignant B-cells. Antibody fragments according to the invention normally comprise an idiotype.
  • a tumor cell associated antigen is a molecule produced by or associated with malignant cells, but is not normally expressed, or expressed at very low levels, by a non-malignant cell.
  • a lipid is any of a group of biochemicals which are variably soluble in organic solvents, such as alcohol.
  • examples of lipids include phospholipids, fats, waxes, and sterols, such as cholesterol.
  • a vaccine is a material that is administered to a vertebrate host to immunize the host against the same material.
  • a vaccine comprises material associated with a disease state, such as viral infection, bacterial infection, and various malignancies.
  • An antigen according to the present invention can be an antibody molecule produced by the malignant B-cell or a fragment of such an antibody.
  • the antibodies associated with B cells typically contain a transmembrane domain.
  • chronic lymphocytic leukemia such antibodies also have a transmembrane domain.
  • the malignant B-cells often secrete fragments of antibodies.
  • these antibodies will be derived from the patient to be treated for B-cell malignancy.
  • the antibodies can be extracted from a sample of tissue containing malignant B-cells which has been obtained from a patient with a B-cell malignancy. Typically such a tissue sample will be taken from the lymph nodes of the patient.
  • antibodies can be extracted from the patient's serum and urine. It is known in the art that certain antibody light chain molecules are associated with multiple myeloma.
  • One example of such a protein is a Bence-Jones protein. Using protein extraction and purification procedures well known to those of skill in the art, the B-cell antibodies can be isolated and purified.
  • isolation and purification techniques include affinity chromatography, for example with protein-A sepharose, size exclusion chromatography and ion-exchange chromatography. See, for example, CURRENT PROTOCOLS IN IMMUNOLOGY, VOL 1, pages 2.7.1-2.7.12 (John Wiley & Sone 1991), METHODS IN MOLECULAR BIOLOGY, VOL. 10, pages 79-104 (The Humana Press, Inc. 1992). It is also known in the art that three major idiotypes are associated with chronic lymphocytic leukemia.
  • the patient tissue sample containing malignant B cells will be used to create monoclonal antibodies in vitro .
  • malignant tissue, containing malignant B-cells is fused with a mouse cell line to produce a hybridoma cell line that will produce a malignant B-cell-associated antibody.
  • Techniques for making monoclonal antibodies are well known to those of skill in the art. See, for example, Kohler and Millstein, Nature 256: 495 (1975) and CURRENT PROTOCOLS IN IMMUNOLOGY, VOL 1, pages 2.5.1-2.6.7 (John Wiley & Sone 1991)
  • the antigen will comprise a fragment of an antibody produced by malignant B-cells. Such a fragment will comprise an idiotype associated with the malignant B-cell.
  • An antibody fragment according to the invention includes (A) a "half antibody" molecule, i.e ., a single heavy:light chain pair, and (B) an enzymatically cleaved antibody fragment, such as the univalent fragments Fab and Fab', the divalent fragment F(ab') 2 , and a single or double chain Fv fragment.
  • An Fv fragment of an antibody is made up of the variable region of the heavy chain (Vh) of an antibody and the variable region of the light chain of an antibody (Vl).
  • fragments within the invention can be obtained from an antibody by methods that include digestion with proteases such as pepsin or papain and/or cleavage of disulfide bonds by chemical reduction.
  • antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab') 2 .
  • This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments.
  • antibody fragments encompassed by the present invention can be synthesized using an automated peptide synthesizer such as those supplied commercially by Applied Biosystems, Multiple Peptide Systems and others, or they may be produced manually, using techniques well known in the art. See Geysen et al., J. Immunol. Methods 102: 259 (1978). Direct determination of the amino acid sequences of the variable regions of the heavy and light chains of the antibodies according to the invention can be carried out using conventional techniques.
  • Proteolytic cleavage of an antibody can produce double chain Fv fragments in which the Vh and Vl regions remain non-covalently associated and retain antigen binding capacity.
  • Double chain Fv fragments also can be produced by recombinant expression methods well known in the art. See Skerra et al., Science 240: 1038 (1988), and King et al., Biochemical J. 290: 723 (1991).
  • the amino acid sequence of the variable regions of the heavy and light chains of antibodies according to the invention can be obtained by direct amino acid sequencing using methods well known to those in the art. From this amino acid sequence, synthetic genes can be designed which code for these variable regions and they can both be inserted into an expression vector. Two polypeptides can be expressed simultaneously from a mammalian or bacterial host, resulting in formation of an active Fv fragment.
  • An antigen of the present invention also can be a "single chain antibody," a phrase used in this description to denote a linear polypeptide that binds antigen with specificity and that comprises variable or hypervariable regions from the heavy and light chain chains of an antibody.
  • Other single chain antibodies according to the invention can be produced by conventional methodology.
  • the Vh and Vl regions of the Fv fragment can be covalently joined and stabilized by the insertion of a disulfide bond. See Glockshuber, et al., Biochemistry 1362 (1990). Alternatively, the Vh and Vl regions can be joined by the insertion of a peptide linker.
  • Vh, Vl and peptide linker sequences can be constructed and expressed using a recombinant expression vector. See Colcher, et al., J. Nat'l Cancer Inst . 82: 1191 (1990). Amino acid sequences comprising hypervariable regions from the Vh and Vl antibody chains can also be constructed using disulfide bonds or peptide linkers, as described herein.
  • CDR peptides constituting a single complementarity-determining region (CDR).
  • CDR peptides such as CDR3, ("minimal recognition units") can be obtained by constructing and expressing genes encoding the CDR of an antibody of interest.
  • genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick et al., Methods: A Companion to Methods in Enzymology 2 : 106 (1991).
  • compositions of the invention can also comprise B-cell antigens which are not specifically associated with malignant B-cells ("non-malignancy associated B-cell antigens").
  • non-malignancy associated B-cell antigens are known in the art and include CD19, CD20, CD21, CD22, CD23, CD25, CD5, and FMC7.
  • FMC7 FMC7.
  • FMC7 FMC7.
  • class 1 and class 2 HLA antigens histocompatibility molecules. Class 1 HLA antigens are also found on almost all other mammalian cells.
  • TAAs tumor-associated antigens
  • compositions of the invention can additionally comprise other TAAs.
  • tumor-associated antigen examples include MUC-1, EBV antigen and antigens associated with Burkitt's lymphoma.
  • Liposomes are microscopic vesicles that consist of one or more lipid bilayers surrounding aqueous compartments. See, generally, Bakker-Woudenberg et al., Eur. J. Clin. Microbiol. Infect. Dis. 12 (Suppl. 1) : S61 (1993), and Kim, Drugs 46 : 618 (1993). Liposomes are similar in composition to cellular membranes and as a result, liposomes generally can be administered safely and are biodegradable. Depending on the method of preparation, liposomes may be unilamellar or multilamellar, and liposomes can vary in size with diameters ranging from 0.02 ⁇ m to greater than 10 ⁇ m.
  • agents can be encapsulated in liposomes: hydrophobic agents partition in the bilayers and hydrophilic agents partition within the inner aqueous space(s). See, for example, Machy et al ., LIPOSOMES IN CELL BIOLOGY AND PHARMACOLOGY (John Libbey 1987), and ostro et al. , American J. Hosp. Pharm. 46: 1576 (1989).
  • Liposomes can adsorb to virtually any type of cell and then slowly release the encapsulated agent.
  • an absorbed liposome may be endocytosed by cells that are phagocytic. Endocytosis is followed by intralysosomal degradation of liposomal lipids and release of the encapsulated agents. Scherphof et al., Ann. N.Y. Acad. Sci. 446 : 368 (1985).
  • cationic liposomes are the most studied, due to their effectiveness in mediating mammalian cell transfection in vitro. They are often used for delivery of nucleic acids, but can be used for delivery of other therapeutics, be they drugs or hormones.
  • Cationic lipids are not found in nature and can be cytotoxic, as these complexes appear incompatible with the physiological environment in vivo which is rich in anionic molecules. Liposomes are preferentially phagocytosed into the reticuloendothelial system. However, the reticuloendothelial system can be circumvented by several methods including saturation with large doses of liposome particles, or selective macrophage inactivation by pharmacological means. Claassen et al., Biochim. Biophys. Acta 802: 428 (1984).
  • glycolipid- or polyethelene glycol-derivatised phospholipids into liposome membranes has been shown to result in a significantly reduced uptake by the reticuloendothelial system.
  • Allen et al. Biochim. Biophys. Acta 1068 : 133 (1991); Allen et al., Biochim. Biohys. Acta 1150 : 9 (1993).
  • Anionic liposomal vectors have also been examined. These include pH sensitive liposomes which disrupt or fuse with the endosomal membrane following endocytosis and endosome acidification.
  • Liposome complexes are sometimes targeted to the cell type or tissue of interest by the addition to the liposome preparation of a ligand, usually a polypeptide, for which a corresponding cellular receptor has been identified.
  • a ligand usually a polypeptide
  • An example of a cell receptor that can be targeted is the folate receptor which has recently been identified as a prominent tumor marker, especially in ovarian carcinomas. KB cells are known to vastly overexpress the folate receptor. Campbell et al. , Cancer Res. 51: 6125-6132 (1991).
  • ligands have been examined for liposome targeting including transferrin, protein A, ApoE, P-glycoprotein, ⁇ 2 -macroglobin, insulin, asiolofetuin, asialoorosomucoid, monoclonal antibodies with a variety of tissue specificity, biotin, galactose or lactose containing haptens (monovalent and tri-antennary), mannose, dinitrophenol, and vitamin B12.
  • the ligands are covalently conjugated to a lipid anchor in either preformed liposomes or are incorporated during liposome preparation.
  • Synthetic peptides are sometimes incorporated into DNA/liposome complexes to enhance their activity, or to target them to the nucleus.
  • the molecule to be delivered in order to gain access to the cytoplasm, the molecule to be delivered must overcome the plasma membrane barrier.
  • viral fusion peptides facilitate the delivery into the cytoplasm by promoting viral membrane fusion with the plasma membrane.
  • the hemagglutinin (trimer) HA peptide N-terminal segment (a hydrophobic helical sequence) is exposed due to a conformational change induced by acidic pH in the endosomes (pH 5-6), inserts into the target membrane, and mediates the fusion between the virus and the target endosomal membrane.
  • acidic pH in the endosomes pH 5-6
  • amphipathic helix-forming oligopeptides have been designed to imitate the behavior of the viral fusion peptide. See, for example, Haensler and Szoka, Bioconj. Chem. 4: 372-79 (1993).
  • Cationic liposome preparations can be made by conventional methodologies. See, for example, Felgner et al., Proc. Nat'l Acad. Sci USA 84:7413 (1987); Schreier, J. of Liposome Res. 2:145 (1992); Chang et al . (1988), supra. Commercial preparations, such as Lipofectin® (Life Technologies, Inc., Gaithersburg, Maryland USA), also are available. For some recent reviews on methods employed see Wassef et al., Immunomethods 4: 217 - 222 (1994) and Weiner, A. L., Immunomethods 4: 217 - 222 (1994).
  • the liposomal preparation could contain one or more adjuvants.
  • a carrier protein such as serum albumin can be added.
  • the dosage of administered liposome preparation will vary depending upon such factors as the patient's age, weight, height, sex, general medical condition and previous medical history. Dose ranges for particular formulations can be determined by using a suitable animal model.
  • Liposomes may be administered to a subject intravenously, intraperitoneally, intrathecally, intramuscularly or subcutaneously. See, for example, Kim, supra , Bakker-Woudenberg et al . (1993), supra , Allen et al . (1993), supra, and Fielding et al., Clin. Pharmacokinetics 21 : 155 (1991).
  • antibodies or fragments are administered to a mammal in a therapeutically effective amount.
  • An antibody preparation is said to be administered in a "therapeutically effective amount” if the amount administered is physiologically significant.
  • An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient mammal.
  • an antibody preparation of the present invention is physiologically significant if its presence invokes a humoral and/or cellular immune response in the recipient mammal.
  • compositions of the present invention comprise cytokines.
  • cytokines include the interferons (INFs) such as INF-gamma, interleukins (ILs), M-CSF, GM-CSF, and tumor necrosis factor.
  • INF- ⁇ induces macrophages, as well as cell-surface class II histocompatibility antigens on lymphoid cells and monocytes. See, for example, Klegerman et al., "Lymphokines and Monokines," in BIOTECHNOLOGY AND PHARMACY, Pezzuto et al .
  • IL-2 is a T cell growth factor and a stimulator of natural killer cells and tumor-reactive T cells. Id. Thus, INF- ⁇ and IL-2 are preferred cytokines for the augmentation of the immune response.
  • Example 1 freeze-thaw procedure for preparation of the vaccine
  • aqueous components Add to the powdered lipid in a 5 mL vial glass vial. Warm for 10 minutes in a 35-39°C water bath. Vortex for 30 seconds. Bath sonicate at 25-45°C for 15 minutes. Freeze the vials in a dry ice/ethanol bath at -80°C for 15 minutes. Thaw in a 35-39°C water bath for 10 minutes. Repeat the vortexing, sonication, freezing and thawing steps a total of three (3) times. Add aqueous buffer to dilute as necessary. The sample may be washed by centrifugation. Centrifuge at 12,000 rpm for 20 minutes. Remove supernatant and wash two more times.
  • Example 1 Hydrate the lipid in aqueous buffer at a concentration of 100-300 mg/mL. Sonicate in a bath sonicator at 30-45°C until clear. Sterile filter through a 0.2 micron filter. Add antigen, IL-2 and serum albumin. Cool sample 4-15°C. This may be temperature cycled any number of times from -80°C to 15°C as the low temperature to 23°C to 50°C as the high temperature. The sample may be diluted as necessary, and washed by centrifugation as in Example 1.
  • the sample from Examples 1-3 may be size-reduced by extrusion through a 1.0, 0.4 and 0.2 micron polycarbonate filter.
  • the final size should be between 100 - 200 nm.
  • OncoVAX The vaccine products under this disclosure are called OncoVAX.
  • OncoVAX preparation as well as the (KLH-Id) control was analyzed by determining the amount of antigen (Id), IL-2 and lipid as well as the size of OncoVAX particles.
  • the antigen concentration was determined by a sandwich ELISA method where to unknown antigen bound to rabbit anti mouse IgM a biotinylated rabbit anti mouse IgM was added. To this streptavidin-Europium was added and the Europium fluorescence was measured.
  • Figure 5A reveals the multilamellar liposomes formed. The mean size is roughly 3.0 microns, as determined by single-particle optical sensing (SPOS).
  • Id-KLH was prepared by gluteraldehyde conjugation at a 1:1 ratio of Id and KLH and the dose of Id administered per animal as indicated in parenthesis.
  • a clear dose dependent effect on the induction of protective antitumor immunity was observed, with mice receiving liposomal vaccine formulations delivering 40, 10, and 2 ug Id per mouse demonstrating significantly superior survival compared with controls immunized with free Id. Mice immunized with liposomal vaccines delivering 0.4 ug Id per mouse were not protected from subsequent tumor challenge.
  • IL-2 as a component of the liposomal Id vaccine formulation was investigated by preparing several formulations with serial dilutions of input IL-2, holding the other components constant. Mice immunized with the resulting liposomal formulations, all containing a dose of 40 ug Id, were used to immunize mice. Two weeks later all mice were challenged with 2x 10 3 38C13 cells from a single preparation of tumor and followed for survival. The log rank p values refer to comparisons against three Id groups. The survival patterns of these mice following lethal dose tumor challenge shows a clear IL-2 dose-dependence on the induction of protective antitumor immunity.
  • the representative experiment demonstrates a significant T cell proliferative response to Id but not among groups primed with empty liposomes or free Id. These results are also particularly revealing, because such evidence of T cell activation has never been observed after immunization with Id-KLH and was not observed with an Id-cytokine fusion protein.
  • mice were immunized with a single liposomal Id vaccine preparation two weeks after immunization, eight mice per group were randomly assigned to receive treatment with depleting mAb specific for either CD4+ ((GK1.5, ammonium sulfate purified assightese from the BRMP pre-clinical repository, Frederick, MD), CD8+ T cells (53.6-72, ammonium sulfate purified assightese from the BRMP pre-clinical repository, Frederick, MD), a combination of the two antibodies, or with normal rat IgG (Sigma, St.Louis, MO) every other day for three doses, just prior to challenge with a single preparation of tumor.
  • CD4+ ((GK1.5, ammonium sulfate purified assightese from the BRMP pre-clinical repository, Frederick, MD)
  • CD8+ T cells 53.6-72, ammonium sulfate purified assightese from the BRMP pre-clinical repository,
  • mice were injected with 10 4 38C13 tumor cells s.c. and then immunized i.p. as indicated later the same day (day 0). All groups received CTX 75 mg/kg i.p. on day 10. Mice surviving >60 days without tumor relapse were apparently cured.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (25)

  1. Therapeutische Liposomzusammensetzung, umfassend:
    a) mindestens ein mit einem bösartigen B-Zell-Tumor verbundenes Antigen, wobei das Antigen einen Antikörper oder ein Antikörperfragment, enthaltend einen Idiotyp, umfasst und wobei der Antikörper oder das Fragment aus einer bösartigen B-Zelle extrahiert wird;
    b) Interleukin-2, allein oder in Kombination mit mindestens einem anderen Cytokin; und
    c) mindestens einen Lipidmolekültyp.
  2. Zusammensetzung nach Anspruch 1, wobei die bösartige B-Zelle mit einem Lymphom, chronischer Leukämie oder multiplem Myelom verbunden ist.
  3. Zusammensetzung nach Anspruch 1 oder Anspruch 2, die zusätzlich ein mit einem Tumor verbundenes Antigen umfasst, bei welchem es sich um keinen Antikörper oder um kein Antikörperfragment handelt.
  4. Zusammensetzung nach Anspruch 3, wobei das mit einem Tumor verbundene Antigen MUC-1-, EBV-Antigen oder ein mit Burkitt-Lymphom verbundenes Antigen ist.
  5. Zusammensetzung nach einem der Ansprüche 1 bis 4, des Weiteren umfassend ein B-Zellen-Antigen, das durch nicht bösartige B-Zellen hergestellt oder damit verbunden ist.
  6. Zusammensetzung nach Anspruch 5, wobei das B-Zellen-Antigen ein HLA-Antigen der Klasse 1 oder Klasse 2 ist.
  7. Zusammensetzung nach einem der Ansprüche 1 bis 6, wobei das mindestens eine andere Cytokin M-CSF, GM-CSF oder IFN-Gamma ist.
  8. Zusammensetzung nach einem der Ansprüche 1 bis 7, wobei das Lipidmolekül ein Phospholipid, ein Glycolipid, Cholesterin oder ein Derivat der Lipide ist.
  9. Zusammensetzung nach einem der Ansprüche 1 bis 8, wobei das IL-2 in einer Konzentration von mindestens 1 x 104 IU/ml Impfstoff vorliegt.
  10. Zusammensetzung nach einem der Ansprüche 1 bis 9, wobei das mit einem bösartigen B-Zell-Tumor verbundene Antigen ein Id-Antigen ist, das in einer Konzentration von 1 bis 200 µg/ml vorliegt.
  11. Zusammensetzung nach einem der Ansprüche 1 bis 10, des Weiteren umfassend ein Trägerprotein.
  12. Zusammensetzung nach Anspruch 11, wobei das Trägerprotein Albumin ist.
  13. Zusammensetzung nach einem der Ansprüche 1 bis 12, des Weiteren umfassend ein pharmazeutisch verträgliches Impfstoffvehikulum.
  14. Verwendung einer Zusammensetzung nach einem der Ansprüche 1 bis 13 bei der Herstellung eines Medikaments für:
    a) die Behandlung eines bösartigen B-Zell-Tumors oder
    b) das Induzieren von humoralen und zellulären Antworten auf bösartige B-Zellen in einem Säuger.
  15. Verfahren zur Herstellung einer therapeutischen Liposomzusammensetzung, umfassend:
    a) Kombinieren von Folgendem:
    i) mindestens eines mit einem bösartigen B-Zell-Tumor verbundenen Antigens, wobei das Antigen einen Antikörper oder ein Antikörperfragment, enthaltend einen Idiotyp, umfasst und wobei der Antikörper oder das Fragment aus einer bösartigen B-Zelle extrahiert wird;
    ii) Interleukin-2, allein oder in Kombination mit mindestens einem anderen Cytokin; und
    iii) mindestens eines Lipidmolekültyps, und
    b) dreimaliges Einfrieren und Auftauen der Zusammensetzung von Schritt a) um eine therapeutische Liposomzusammensetzung zu erhalten.
  16. Verfahren zur Herstellung einer therapeutischen Liposomzusammensetzung, umfassend:
    a) Bereitstellen mindestens eines Lipids in einem wässrigen Puffer;
    b) Zugabe zum Lipid von Schritt a):
    i) mindestens eines mit einem bösartigen B-Zell-Tumor verbundenen Antigens, wobei das Antigen einen Antikörper oder ein Antikörperfragment, enthaltend einen Idiotyp, umfasst und wobei der Antikörper oder das Fragment aus einer bösartigen B-Zelle extrahiert wird; und
    ii) IL-2 und Serumalbumin; und
    c) mindestens einmaliges Mischen der Zusammensetzung von Schritt b) von einer niedrigen Temperatur von -80°C bis 15°C auf eine hohe Temperatur von 23°C bis 50°C, zum Erhalt einer therapeutischen Zusammensetzung.
  17. Verfahren zur Herstellung einer therapeutischen Liposomzusammensetzung, umfassend:
    a) Bereitstellen mindestens eines Lipids in einem wässrigen Puffer;
    b) Zugabe zum Lipid von Schritt a):
    i) mindestens eines mit einem bösartigen B-Zellentumor verbundenen Antigens, wobei das Antigen einen Antikörper oder ein Antikörperfragment, enthaltend einen Idiotyp, umfasst und wobei der Antikörper oder das Fragment aus einer bösartigen B-Zelle extrahiert wird; und
    ii) IL-2 und Mäuseserumalbumin; und
    c) Mischen der Zusammensetzung von Schritt b) mit Polyethylenglycol mit einem Molekulargewicht zwischen 1000 und 20000 in Form einer 6-60%igen (G/V) Lösung zum Erhalt einer therapeutischen Zusammensetzung.
  18. Verfahren nach einem der Ansprüche 15 bis 17, wobei die therapeutische Liposomzusammensetzung zur Herstellung einer Endgröße von 100 bis 200 nm durch einen Filter extrudiert wird.
  19. Verfahren nach einem der Ansprüche 15 bis 18, wobei die bösartige B-Zelle mit Lymphom, chronischer Lymphozytenleukämie oder multiplem Myelom verbunden ist.
  20. Verfahren nach einem der Ansprüche 15 bis 19, wobei das mindestens eine mit einem bösartigen B-Zell-Tumor verbundene Antigen ausgewählt ist aus der Gruppe, bestehend aus Antikörpern, Antikörperfragmenten, hergestellt durch bösartige B-Zellen, Antigenen, bei welchen es sich um keine Antikörper handelt und die durch bösartige B-Zellen hergestellt werden, Antigenen, bei welchen es sich um keine Antikörper handelt und die mit bösartigen B-Zellen verbunden sind, und Gemischen davon.
  21. Verfahren nach einem der Ansprüche 15 bis 20, des Weiteren umfassend ein B-Zellen-Antigen, das durch nicht bösartige B-Zellen hergestellt oder mit diesen verbunden ist.
  22. Verfahren nach Anspruch 21, wobei das B-Zellen-Antigen ein HLA-Antigen der Klasse 1 oder Klasse 2 ist.
  23. Verfahren nach einem der Ansprüche 15 bis 22, wobei das mindestens eine andere Cytokin M-CSF, GM-CSF oder IFN-Gamma ist.
  24. Verfahren nach einem der Ansprüche 15 bis 23, wobei das Lipidmolekül ein Phospholipid, ein Glycolipid, Fett, Wachs, Sterol, Cholesterin oder ein Derivat der Lipide ist.
  25. Verfahren nach einem der Ansprüche 15 bis 24, des Weiteren umfassend ein pharmazeutisch verträgliches Impfstoffvehikulum.
EP97905966A 1996-02-16 1997-02-13 Impfstoff gegen tumore der b-lymphozyten Expired - Lifetime EP0918539B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1178396P 1996-02-16 1996-02-16
US11783P 1996-02-16
PCT/US1997/002351 WO1997029769A1 (en) 1996-02-16 1997-02-13 Vaccine for b-cell malignancies

Publications (3)

Publication Number Publication Date
EP0918539A1 EP0918539A1 (de) 1999-06-02
EP0918539A4 EP0918539A4 (de) 2001-04-11
EP0918539B1 true EP0918539B1 (de) 2005-10-19

Family

ID=21751949

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97905966A Expired - Lifetime EP0918539B1 (de) 1996-02-16 1997-02-13 Impfstoff gegen tumore der b-lymphozyten

Country Status (8)

Country Link
US (2) US6312718B1 (de)
EP (1) EP0918539B1 (de)
JP (1) JP3948751B2 (de)
AT (1) ATE306937T1 (de)
AU (1) AU2273497A (de)
CA (1) CA2246708C (de)
DE (1) DE69734392T2 (de)
WO (1) WO1997029769A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN190388B (de) * 1997-10-01 2003-07-26 Biomira Usa Inc
EP1523977A1 (de) * 1997-10-01 2005-04-20 Biomira Usa Inc. Biologisch aktive Verbindungen enthaltende multilamellare Koaleszenzvesikel (MLCV)
JP2002509114A (ja) 1998-01-16 2002-03-26 バイオミラ・ユーエスエイ・インコーポレイテッド 膜プロテオリポソームから作製される患者特異的白血球悪性腫瘍ワクチン
AU756570B2 (en) * 1998-01-16 2003-01-16 Biomira Inc. Lipomatrix preparation
DE19954843C2 (de) * 1999-11-09 2003-11-20 Novosom Ag Verfahren zur Verkapselung von Proteinen oder Peptiden in Liposomen, mit dem Verfahren hergestellte Liposomen und deren Verwendung
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
HK1052314A1 (zh) * 2000-08-11 2003-09-11 Favrille, Inc. 改变t细胞介导的病理的方法和组合物
JP2005525992A (ja) * 2001-06-25 2005-09-02 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム 生物学的物質を充填した小胞の調製法およびそれらの様々な使用
FR2934498B1 (fr) * 2008-08-01 2014-08-15 Commissariat Energie Atomique Utilisation d'une forme soluble d'hla-g dans le traitement des proliferations anormales des lymphocytes b.
US8647627B2 (en) 2011-01-13 2014-02-11 Oncbiomune, L.L.C. Composition for a cancer vaccine
WO2014036488A1 (en) 2012-08-31 2014-03-06 Biovest International, Inc. Methods for producing high-fidelity autologous idiotype vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409698A (en) * 1988-10-27 1995-04-25 The Regents Of The University Of Minnesota Liposome immunoadjuvants containing IL-2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
AU5361794A (en) * 1992-10-14 1994-05-09 Board Of Trustees Of The Leland Stanford Junior University Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates
US5861158A (en) * 1993-11-17 1999-01-19 The United States Of America As Represented By The Deptartment Of Health And Human Services Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409698A (en) * 1988-10-27 1995-04-25 The Regents Of The University Of Minnesota Liposome immunoadjuvants containing IL-2

Also Published As

Publication number Publication date
EP0918539A4 (de) 2001-04-11
US20030021838A1 (en) 2003-01-30
ATE306937T1 (de) 2005-11-15
DE69734392T2 (de) 2006-07-13
CA2246708A1 (en) 1997-08-21
EP0918539A1 (de) 1999-06-02
CA2246708C (en) 2005-06-14
JP2000507214A (ja) 2000-06-13
JP3948751B2 (ja) 2007-07-25
US6312718B1 (en) 2001-11-06
WO1997029769A1 (en) 1997-08-21
DE69734392D1 (de) 2006-03-02
AU2273497A (en) 1997-09-02

Similar Documents

Publication Publication Date Title
Gregoriadis et al. Liposomes as immunological adjuvants and vaccine carriers
Bei et al. The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice
JP4970035B2 (ja) ｉｎｖｉｖｏにおける樹状細胞の標的化
EP0918539B1 (de) Impfstoff gegen tumore der b-lymphozyten
CN111954541A (zh) 包含可溶性包封抗原的聚合物囊泡以及其制备方法和用途
JP4210519B2 (ja) 低免疫原性抗原の免疫原性を増強する医薬組成物
JP4774551B2 (ja) 抗癌ワクチン接種のための抗体の使用
WO1997029769A9 (en) Vaccine for b-cell malignancies
JP2004523494A6 (ja) 低免疫原性抗原の免疫原性を増強する医薬組成物
AU781376B2 (en) Telomerase-specific cancer vaccine
EP1377275B1 (de) Impfstoff zur modulation zwischen t1 und t2 immunantworten
AU2002309141A1 (en) Vaccine for modulating between T1 and T2 immune responses
Pawlak-Roblin et al. Inhibition of multidrug resistance by immunisation with synthetic P-glycoprotein-derived peptides
Johnston et al. Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice
CN119522232A (zh) 用于预防和治疗癌症的抗原肽
US20230381309A1 (en) Methods of treating diffuse large b-cell lymphoma
Pietrobon et al. Lipopeptides and Their Effects on the Immune System: Use as Vaccine Components
Guan Development of liposomal antigen delivery system for synthetic MUC1 peptides.
Gregoriadis et al. The Immunoadjuvant Action of Liposomes: Optimization Studies
Gregoriadis et al. Medical Research Council Group, Academic Department of Medicine, Royal Free Hospital School of Medicine, Pond Street

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980915

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010222

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020604

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051019

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051019

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051019

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051019

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051019

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051019

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060119

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060119

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060228

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060228

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060228

Year of fee payment: 10

REF Corresponds to:

Ref document number: 69734392

Country of ref document: DE

Date of ref document: 20060302

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060320

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20060720

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20090220

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20090219

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20090219

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070213

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20090220

Year of fee payment: 13

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20100213

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20101029

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100215

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100213